// App-Quantinova.ai

5294 : MDX-124, a novel annexin-A1 antibody, induces significant anti-cancer activity in multiple preclinical models

Researchers

Presenter

  • Fiona C. Dempsey

Principal Investigators

  • Hussein Al-Ali

  • Scott J. Crichton

  • Charlene Fabian

  • Chris Pepper

  • Bin-Zhi Qian

  • Xue-Feng Li

  • Christopher N. Parris

Medical Centers

  • Medannex Limited, Edinburgh, United Kingdom

  • INIVATA, Cambridge, United Kingdom

  • Brighton and Sussex Medical School, Brighton, United Kingdom

  • The University of Edinburgh, Edinburgh, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Prostate cancer

  • Solid malignancies

  • Pancreatic and cerebellar agenesis

  • Triple-negative breast cancer

Biomarkers

  • Annexin A1

  • Melanoma-inhibitory activity

  • Jagged canonical Notch ligand 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • First-In-Human

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved